ScreenerHero

CAPRCapricor Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · capricor.com
6.290USD-21.18%Mkt Cap: 365.69M $P/E: —

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap365.69M $
Enterprise Value250.49M $
Revenue (TTM)—
Gross Profit-99.73M $
Net Income (TTM)-105.04M $
Revenue/Share—
Last Price6.290 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS14070B3096
Valuation
P/E (Trailing)—
P/E (Forward)-4.48
PEG0.38
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B1.61
EPS (TTM)-2.10
EPS (Forward)-1.53
52W Range
2.9609% of range40.37
52W High40.37 USD
52W Low2.960 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.35%
ROA-29.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.81M $
CapEx (TTM)11.72M $
FCF Margin—
FCF Yield-24.39%
Net Debt-146.89M $
Net Debt/EBITDA1.10
Balance Sheet
Debt/Equity0.05
Current Ratio7.35
Quick Ratio7.22
Book Value/Sh4.237 USD
Cash/Share4.093 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 5, 2019
Splits
Last Split1:10
Split DateJun 5, 2019
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.50 USD
Upside (mean)+66.9%
Target Range2.000 USD – 28.00 USD
$2.000+66.9% to mean$28.00
# Analysts4
Ownership
Shares Out.58.14M
Float45.55M
Insiders9.44%
Institutions71.56%
Short Interest
Short Ratio3.3d
Short % Float30.49%
Short % Out.27.60%
Shares Short15.98M
Short (prev mo.)14.74M
Technical
SMA 5016.69 (-62.3%)
SMA 20023.20 (-72.9%)
Beta0.53
S&P 52W Chg18.16%
Avg Vol (30d)7.81M
Avg Vol (10d)14.02M
Technical Indicators
RSI (14)34.1
MACD-3.4199
MACD Signal-4.3189
MACD Hist.+0.8990
BB Upper18.14 USD
BB Middle7.258 USD
BB Lower-3.6280 USD
BB Width299.97%
ATR (14)1.511 USD
Vol Ratio (20d)0.77x